Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.47 |
| ▸ | CDC25B | P30305 | 8/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.43 |
| ▸ | GJB2 | P29033 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25914408 | 0.92 | GJB2 (0.49) | PTPN1CDC25BSLC6A2GJB2 | |
| SCHEMBL13608236 | 0.89 | PTPN1 (0.53) | PTPN1CDC25BPTPN2PTPN11PTPN6 | |
| SCHEMBL25913933 | 0.86 | GJB2 (0.48) | NT5ESLC6A2GJB2 | |
| SCHEMBL19731881 | 0.82 | PTPN1 (0.40) | PTPN1CDC25BPTPN2PTPN11NT5E | |
| SCHEMBL25913717 | 0.81 | SSTR5 (0.50) | PTPN1CDC25BPTPN2PTPN11PTPN6 | |
| SCHEMBL30140820 | 0.81 | PTPN1 (0.46) | PTPN1CDC25BPTPN2PTPN11PTPN6 | |
| SCHEMBL14416244 | 0.81 | PTPN1 (0.49) | PTPN1CDC25BPTPN2PTPN11PTPN6 | |
| SCHEMBL21657199 | 0.80 | HTR1A (0.52) | PTPN1CDC25BPTPN2PTPN11PTPN6 | |
| SCHEMBL28943950 | 0.80 | HTR1A (0.52) | PTPN1CDC25BPTPN2PTPN11PTPN6 | |
| SCHEMBL8723384 | 0.80 | HTR1A (0.52) | PTPN1CDC25BPTPN2PTPN11PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218766-A1 | SUGAR COMPOUND HAVING POLYETHYLENE GLYCOL CHAIN, AND PRECURSOR OF ANTIBODY-DRUG COMPLEX | THE NOGUCHI INSTITUTE (JP) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218766-A1 | SUGAR COMPOUND HAVING POLYETHYLENE GLYCOL CHAIN, AND PRECURSOR OF ANTIBODY-DRUG COMPLEX | FCGRT, HBZ, FUT4 | PTPN1 869/4885CDC25B 4210/4885PTPN2 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.